Where's the Promise of Biotech? Featuring Peter Kolchinsky

This month, Peter Kolchinsky of RA Capital joins Greg to discuss biotech innovation and investment strategy, and where science will take society next.

In this episode of the FEG Insight Bridge Podcast, Greg Dowling speaks with Peter Kolchinsky, Managing Partner at RA Capital. Together they delve into the drivers and details of today’s biotech industry, how to foster innovation and why Peter is optimistic about biotech’s ability to address autoimmune disorders. Peter shares RA Capital’s investment approach, which emphasizes patience, rigor and selectiveness across healthcare and life science sectors.

Listen to an insightful, actionable discussion on the forces shaping biotech investing today and likely to shape it tomorrow.

Key Takeaways:

• Peter emphasizes the importance of fostering innovation, especially in the biopharmaceutical industry.
• RA Capital’s investment philosophy centers on long-term value creation, focusing on select companies within the space that address significant unmet medical needs and have strong scientific foundations.
• Kolchinsky critiques current drug pricing debates, arguing that attempts to control costs in the short term could harm future innovation and patient outcomes.
• Despite vaccine concerns, political uncertainty and the continual headwind of expiring patents, Peter’s outlook for biotech — especially the potential to address autoimmune disorders — is strong.

Episode Chapters